Renalytix AI PLC Notice of Results & Change of Auditor (4033B)

TIDMRENX

RNS Number : 4033B

Renalytix AI PLC

10 June 2021

Renalytix AI plc

("Renalytix" or the "Company")

Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update

Announces Change of Auditor to Ernst & Young LLP

NEW YORK, June 10, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open. The Company will host a corresponding conference call and live webcast at 8:30 a.m. (EDT) / 1:30 p.m. (BST) to discuss the results and provide a corporate update.

Conference Call Details:

US/Canada Participant Toll-Free Dial-In Number: [phone]

US/Canada Participant International Dial-In Number: [phone]

United Kingdom International Dial-In Number: 0800 9174 860

United Kingdom Local Dial-In Number: 0203 1070 289

Conference ID:9287147

Webcast Registration link: https://edge.media-server.com/mmc/p/saaze8yw

Auditor Change

The Audit Committee of the Company's Board of Directors approved the dismissal of Deloitte & Touche LLP effective May 12, 2021. Ernst & Young LLP has been appointed as the Company's successor auditor for U.S. reporting, effective May 12, 2021, and for the fiscal year ended June 30, 2021. PKF Littlejohn LLP remains the Company's U.K. statutory auditors.

There were no disagreements with Deloitte on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures.

For further information, please contact:

UK Investor Contact:

 
Walbrook PR Limited        Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne            Mob: [phone] 
                                                                      303 
 
 

US Investor Contact:

 
Gilmartin Group                                   i [e-mail] 
Carrie Mendivil / Mary Kate McDonough                         415-937-5405 
 
 

About Renalytix

Renalytix is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Renalytix's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytix.com .

Forward Looking Statements

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should, " "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue, " "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSSEESUEFSESM

(END) Dow Jones Newswires

June 10, 2021 02:00 ET (06:00 GMT)